Screener
Candel Therapeutics, Inc. CADL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Research and development | $9,840 | $4,016 |
| General and administrative | 6,444 | 4,114 |
| Total operating expenses | 16,284 | 8,130 |
| Loss from operations | (16,284) | (8,130) |
| Other income (expense): | ||
| Grant income | 22 | — |
| Interest income | 1,322 | 934 |
| Interest expense | (1,564) | (306) |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s operating income?
- Candel Therapeutics, Inc. (CADL) reported operating income of -$16.28M in Q1 2026.
- How has Candel Therapeutics, Inc.'s operating income changed year-over-year?
- Candel Therapeutics, Inc.'s operating income decreased by 100.3% year-over-year, from -$8.13M to -$16.28M.
- What is the long-term trend for Candel Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s operating income has grown at a 17.0% compound annual growth rate (CAGR), from -$25.73M to -$48.27M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Candel Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude